Please login to the form below

Not currently logged in

Deal Watch table for September 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during September 2013.

For an indepth analysis of these deals, read 'Pharma deals during September 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

GlaxoSmithKline / Suntory Beverage & FoodAcquisition of assets Lucozade and Ribena soft drink brands2,116
Adcock Ingram / CFR Pharmaceuticals Acquisition
South African generics and anti-retrovirals company

Astex Pharma / Otsuka PharmaAcquisitionOncology biotech company886
Ablynx  / AbbVie1Licence
ALX0061 - anti-IL-6R nanobody for rheumatoid arthritis and lupus
GSK / Aspen PharmacareAcquisition of assets2Arixtra and Fraxiparine - anti-thrombotic agents700
Gland Pharma / KKRAcquisition (40 per cent)Indian generics company 500
Egis / ServierAcquisition (49 per cent)3Hungarian pharmaceutical company483
BioFire Diagnostics / BioMerieuxAcquisitionInvitro diagnostic company450
Inovio Pharma / Roche HoldingsLicenceDNA immunoptherapy vaccines targeting prostate cancer (INO5150)  and Hepatitis B (INO-1800), plus CELECTRA delivery technology423
Galapagos / AbbVieGlobal allianceNovel potentiator / combination therapies in cystic fibrosis focussing on F508del and G551D mutations405
Medytox / Allergan4LicenceNeurotoxin product candidates362
Isis Pharma / Biogen IdecTechnology allianceAntisense technology focusing on therapies for neurological diseases320
Cornerstone Therapeutics/ Chiesi FarmaceuticiAcquisition (42 per cent)US speciality pharmaceutical company focused hospital and niche respiratory products255
Coherus Biosciences / Baxter InternationalLicenceEtanercept biosimilar for rhematoid arthritis246
Laboratorios Casen Fleet/ RecordatiAcquisitionSpanish pharmaceutical company123
Pacific Biosciences of California/Roche DiagnosticsLicenceDiagnostic products IVD75
Merck & Co / AstraZenecaLicenceWEE1 kinase (MK-1775) for ovarian cancer505
Shin Nippon Biomedical  / Transcept PharmaLicenceTO-2070 nasal powder for acute migraine43
Innovus Pharma / Ovation PharmaLicenceEjectDelay /  CIRCUMserum39
Ablynx / Merck Serono Research allianceUse of nanobody platform across Merck Serono's core disease areas (oncology, immuno-oncology, immunology and neurology)33 


1. Global option to in-licence product … Ablynx to retain co-promotion rights in Belgium, Netherlands and Luxembourg

2. Global rights excluding India, Pakistan and China

3. Acquisition of the shares not already owned by Servier and Chiesi, ie 51 per cent in Egis and 58 per cent of Cornerstone Therapeutics, respectively

4. Global rights excluding South Korea

5. Only upfront of $50m is disclosed, but Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties.


The Deal Watch table is compiled by Medius Associates

15th October 2013

The Deal Watch table is compiled by Medius Associates

15th October 2013

From: Research, Sales



Career advice

No results were found

COVID-19 Updates and Daily News

Featured jobs


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...